PI3K/AKT/mTOR pathway inhibitors have emerged as a promising class of targeted therapies for the treatment of cSCC (Jiang et al., 2020[89]; Ye et al., 2023[188]). This evidence concerns the gene PIK3CA and skin squamous cell carcinoma.